Trial Profile
A Phase 1, Randomized, Three-Arm, Double-Blind, Single-Dose Study To Compare The Pharmacokinetics And Safety Of The Potential Biosimilar NeuLara With Ustekinumab In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors NeuClone
- 20 Oct 2020 Primary endpoint (To evaluate the PK similarity of Neulara with Stelara-EU and Stelara-US reference products following single SC injection of 45 mg/0.5 ml in healthy volunteers) has been met, according to a NeuClone media release,
- 20 Oct 2020 Results announced in a NeuClone media release.
- 08 Apr 2020 Status changed from active, no longer recruiting to completed, according to a NeuClone Pharmaceuticals media release.